MC2313A1 - ENZYME INHIBITORS - Google Patents

ENZYME INHIBITORS

Info

Publication number
MC2313A1
MC2313A1 MC912313D MC2313D MC2313A1 MC 2313 A1 MC2313 A1 MC 2313A1 MC 912313 D MC912313 D MC 912313D MC 2313 D MC2313 D MC 2313D MC 2313 A1 MC2313 A1 MC 2313A1
Authority
MC
Monaco
Prior art keywords
enzyme inhibitors
inhibitors
enzyme
Prior art date
Application number
MC912313D
Other languages
French (fr)
Inventor
Michael Szelke
David Michael Evans
David Jones
Original Assignee
Ferring Peptide Research Partn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Peptide Research Partn filed Critical Ferring Peptide Research Partn
Publication of MC2313A1 publication Critical patent/MC2313A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0227—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the (partial) peptide sequence -Phe-His-NH-(X)2-C(=0)-, e.g. Renin-inhibitors with n = 2 - 6; for n > 6 see C07K5/06 - C07K5/10

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
MC912313D 1990-09-07 1991-09-02 ENZYME INHIBITORS MC2313A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909019558A GB9019558D0 (en) 1990-09-07 1990-09-07 Enzyme inhibitors

Publications (1)

Publication Number Publication Date
MC2313A1 true MC2313A1 (en) 1993-09-27

Family

ID=10681831

Family Applications (1)

Application Number Title Priority Date Filing Date
MC912313D MC2313A1 (en) 1990-09-07 1991-09-02 ENZYME INHIBITORS

Country Status (13)

Country Link
EP (1) EP0652893A1 (en)
JP (1) JPH06501461A (en)
AU (1) AU8438791A (en)
CA (1) CA2090858A1 (en)
FI (1) FI930946A (en)
GB (1) GB9019558D0 (en)
HU (1) HUT64084A (en)
IE (1) IE913120A1 (en)
MC (1) MC2313A1 (en)
NO (1) NO930731L (en)
PT (1) PT98885A (en)
WO (1) WO1992004371A1 (en)
ZA (1) ZA917096B (en)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9103612D0 (en) * 1991-12-04 1991-12-04 Astra Ab NEW PEPTIDE DERIVATIVES
US5374623A (en) * 1992-08-20 1994-12-20 Prototek, Inc. Cysteine protease inhibitors effective for in vivo use
US6984627B1 (en) 1993-06-03 2006-01-10 Astrazeneca Ab Peptide derivatives
SE9301911D0 (en) * 1993-06-03 1993-06-03 Ab Astra NEW PEPTIDE DERIVATIVES
SE9301916D0 (en) * 1993-06-03 1993-06-03 Ab Astra NEW PEPTIDES DERIVATIVES
US5780631A (en) * 1993-06-03 1998-07-14 Astra Aktiebolag Starting materials in the synthesis of thrombin and kininogenase inhibitors
GB9318637D0 (en) * 1993-09-08 1993-10-27 Ferring Res Ltd Enzyme inhibitors
US5486623A (en) 1993-12-08 1996-01-23 Prototek, Inc. Cysteine protease inhibitors containing heterocyclic leaving groups
SE9404196D0 (en) * 1994-12-02 1994-12-02 Astra Ab New antithrombotic formulation
US5696231A (en) * 1994-12-21 1997-12-09 Corvas International, Inc. N-substituted glycine derivatives as enzyme inhibitors
US6025472A (en) * 1994-12-21 2000-02-15 Corvas International, Inc. N-substituted glycine derivatives as enzyme inhibitors
JP2000500742A (en) 1995-10-30 2000-01-25 スミスクライン・ビーチャム・コーポレイション Protease inhibitor
US6586466B2 (en) 1995-10-30 2003-07-01 Smithkline Beecham Corporation Carbohydrazide-protease inhibitors
TW541316B (en) 1995-12-21 2003-07-11 Astrazeneca Ab Prodrugs of thrombin inhibitors
AU750561B2 (en) 1998-04-24 2002-07-25 3-Dimensional Pharmaceuticals, Inc. Amino acid amidinohydrazones, alkoxyguanidines and aminoguanidines as protease inhibitors
YU42401A (en) 1998-12-14 2003-12-31 Ortho-Mcneil Pharmaceuticals Inc. Substituted heterociclic acyl-tripeptides useful as thrombin receptor modulators
US20030144175A1 (en) 1998-12-23 2003-07-31 Smithkline Beecham Corporation Protease inhibitors
EP1158996A4 (en) 1999-02-18 2005-01-12 Kaken Pharma Co Ltd Novel amide derivatives as growth hormone secretagogues
US6596715B1 (en) 1999-11-10 2003-07-22 Smithkline Beecham Corporation Protease inhibitors
US6583137B1 (en) 1999-11-10 2003-06-24 Smithkline Beecham Corporation Protease inhibitors
AU1474801A (en) 1999-11-10 2001-06-06 Smithkline Beecham Corporation Protease inhibitors
US7071184B2 (en) 2000-03-21 2006-07-04 Smithkline Beecham Corporation Protease inhibitors
GB0205527D0 (en) * 2002-03-08 2002-04-24 Ferring Bv Inhibitors
EP1575991A4 (en) 2002-07-03 2008-03-19 Bio Science International Inc Peptides comprising aromatic d-amino acids and methods of use
FR2846969A1 (en) * 2002-11-08 2004-05-14 Salles Jean Pierre New modified active agent derivatives with improved bioavailability comprising parent drug, e.g. anticancer agent, plus fluorinated hydrocarbon chain and recognition or hydrophilizing moiety
JP4775259B2 (en) 2004-03-31 2011-09-21 味の素株式会社 Aniline derivative
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
GB2494851A (en) 2011-07-07 2013-03-27 Kalvista Pharmaceuticals Ltd Plasma kallikrein inhibitors
GB201212081D0 (en) 2012-07-06 2012-08-22 Kalvista Pharmaceuticals Ltd New polymorph
GB201300304D0 (en) 2013-01-08 2013-02-20 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
PH12015501492A1 (en) 2013-01-08 2015-09-28 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
GB2510407A (en) 2013-02-04 2014-08-06 Kalvista Pharmaceuticals Ltd Aqueous suspensions of kallikrein inhibitors for parenteral administration
PL2999697T3 (en) 2013-05-23 2017-09-29 Kalvista Pharmaceuticals Limited Heterocyclic derivates
WO2015022546A1 (en) 2013-08-14 2015-02-19 Kalvista Pharmaceuticals Limited Inhibitors of plasma kallikrein
TWI636047B (en) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 Heterocyclic derivatives
GB2517908A (en) 2013-08-14 2015-03-11 Kalvista Pharmaceuticals Ltd Bicyclic inhibitors
DK3204352T3 (en) 2014-10-06 2020-09-28 Cortexyme Inc Inhibitors of lysine-gingipain
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
GB201421088D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
GB201421085D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
JP6877424B2 (en) 2015-11-09 2021-05-26 コーテクシーミー， インコーポレイテッド Inhibitor of arginine gingipain
BR112018074395A2 (en) 2016-05-31 2019-03-06 Kalvista Pharmaceuticals Limited pyrazole derivatives as inhibitors of plasma kallikrein
GB201609603D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
AU2017326466B2 (en) 2016-09-16 2021-11-11 Lighthouse Pharmaceuticals, Inc. Ketone inhibitors of lysine gingipain
CN107011217B (en) * 2017-03-24 2018-08-14 东华大学 A kind of fat-soluble 5-ALA derivative and its preparation method and application
CN107043338B (en) * 2017-03-24 2018-09-25 东华大学 A kind of 5-ALA derivative and its preparation method and application
LT3716952T (en) 2017-11-29 2022-04-11 Kalvista Pharmaceuticals Limited Dosage forms comprising a plasma kallikrein inhibitor
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
GB201910116D0 (en) 2019-07-15 2019-08-28 Kalvista Pharmaceuticals Ltd Treatments of hereditary angioedema
GB201910125D0 (en) 2019-07-15 2019-08-28 Kalvista Pharmaceuticals Ltd Treatments of angioedema
WO2021028645A1 (en) 2019-08-09 2021-02-18 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
GB201918994D0 (en) 2019-12-20 2020-02-05 Kalvista Pharmaceuticals Ltd Treatments of diabetic macular edema and impaired visual acuity
GB2591730A (en) 2019-12-09 2021-08-11 Kalvista Pharmaceuticals Ltd New polymorphs
TW202228686A (en) 2020-10-15 2022-08-01 英商卡爾維斯塔製藥有限公司 Treatments of angioedema
WO2022084693A1 (en) 2020-10-23 2022-04-28 Kalvista Pharmaceuticals Limited Treatments of angioedema
EP4291186A1 (en) 2021-02-09 2023-12-20 Kalvista Pharmaceuticals Limited Treatments of hereditary angioedema
WO2023002219A1 (en) 2021-07-23 2023-01-26 Kalvista Pharmaceuticals Limited Treatments of hereditary angioedema
WO2023209381A1 (en) 2022-04-27 2023-11-02 Kalvista Pharmaceuticals Limited Formulations of a plasma kallikrein inhibitor
WO2024180100A1 (en) 2023-02-27 2024-09-06 Kalvista Pharmaceuticals Limited New solid form of a plasma kallikrein inhibitor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0009010B1 (en) * 1978-07-18 1983-03-02 Kabi AB Bradykinin inhibiting tripeptide derivatives, process for their preparation and pharmaceutical preparations containing them
US4563305A (en) * 1981-01-07 1986-01-07 University Of Miami Radiolabelled substrates for assaying mammalian enzymes
US4835253A (en) * 1987-04-03 1989-05-30 The University Hospital Specific inhibitors of tissue kallikrein
ZA897514B (en) * 1988-10-07 1990-06-27 Merrell Dow Pharma Novel peptidase inhibitors

Also Published As

Publication number Publication date
CA2090858A1 (en) 1992-03-08
HU9300610D0 (en) 1993-05-28
ZA917096B (en) 1992-04-29
NO930731D0 (en) 1993-02-26
AU8438791A (en) 1992-03-30
JPH06501461A (en) 1994-02-17
NO930731L (en) 1993-05-07
GB9019558D0 (en) 1990-10-24
PT98885A (en) 1992-08-31
WO1992004371A1 (en) 1992-03-19
IE913120A1 (en) 1992-03-11
FI930946A0 (en) 1993-03-03
EP0652893A1 (en) 1995-05-17
FI930946A (en) 1993-04-26
HUT64084A (en) 1993-11-29

Similar Documents

Publication Publication Date Title
MC2313A1 (en) ENZYME INHIBITORS
NO962269D0 (en) Enzyme inhibitors
DK46793D0 (en) ENZYME
DK48693D0 (en) ENZYME
FI932521A0 (en) Now endoglucan enzyme
DK48893D0 (en) ENZYME
DK154492D0 (en) ENZYME
DE69224225D1 (en) Modified enzyme
FI925166A (en) Proteolytic enzymes inhibit sackarinderivat
DK87592D0 (en) ENZYME
DK39593D0 (en) ENZYME
DK0691887T3 (en) Immobilized enzymes
GB9007750D0 (en) Enzyme inhibitors
DK54190D0 (en) ENZYMES
DK219790D0 (en) ENZYME VARIANTS
DK122292D0 (en) ENZYME
DK154592D0 (en) ENZYME
DK122592D0 (en) ENZYME
DK122492D0 (en) ENZYME
DK122192D0 (en) ENZYME
DK122392D0 (en) ENZYME
DK219490D0 (en) enzyme mutants
IE901320L (en) Inhibitors of enzymes of collagenase family.
DK115990D0 (en) enzyme preparation
DK19693D0 (en) ENZYME